# C3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The C3 gene encodes the central protein of the complement system, acting as a critical convergence point for innate and adaptive immunity, with roles extending to tissue regeneration and metabolic regulation.
- C3's structure features a Thioester-Containing Domain (TED) essential for covalent attachment to target surfaces via opsonization, and its activation fragments, C3a and C3b, mediate inflammatory signaling and phagocytosis, respectively.
- Genetic variants in C3 are strongly associated with complement-mediated kidney diseases like C3 glomerulopathy and aHUS, as well as complex traits such as age-related macular degeneration (AMD) and schizophrenia, highlighting its clinical significance.
- Pathogens employ diverse strategies to evade C3-mediated immunity, including complement inhibitors and Factor H binding, while some viruses exploit C3 receptors for cellular entry.
- Therapeutic strategies targeting C3, such as pegcetacoplan (a C3 inhibitor) and eculizumab (a C5 inhibitor), are approved or under investigation for various complement-mediated disorders, with C3 genetic variants influencing treatment response.

---

## Executive Summary & Key Metadata

The complement component 3 (C3) gene encodes the central protein of the complement system, a critical arm of innate immunity that bridges innate and adaptive immune responses. C3 is the most abundant complement protein in serum (1.0–1.5 mg/mL) and serves as the convergence point for all three complement activation pathways: classical, lectin, and alternative. Beyond its canonical role in pathogen opsonization, immune cell recruitment, and membrane attack complex (MAC) formation, C3 has emerged as a multifunctional protein involved in tissue regeneration, neuronal synapse pruning, metabolic regulation, and cancer biology. The gene's structural complexity, extensive post-translational processing, and tight transcriptional regulation reflect its central position in immune homeostasis. Genetic variants in C3 are associated with a spectrum of diseases ranging from rare complement-mediated kidney disorders to common complex traits such as age-related macular degeneration (AMD) and schizophrenia. This manual provides a comprehensive, biophysically detailed reference on the C3 gene, from genomic architecture to clinical translation.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | C3 |
| UniProt Accession | P01024 |
| Representative PDB ID | 2A73 (C3 native), 3CZT (C3b), 2XQW (C3c) |
| Chromosomal Locus | 19p13.3-p13.2 |
| Primary Molecular Function | Complement activation, opsonization, inflammatory response |
| Disease & Pathology Associations | C3 glomerulopathy, atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), recurrent bacterial infections, systemic lupus erythematosus (SLE), preeclampsia, schizophrenia |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human C3 gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.3-p13.2, spanning approximately 41 kilobases (kb) of genomic DNA. The gene comprises 41 exons and 40 introns, with the coding sequence distributed across exons 1–41 [<a href="#ref-1">1</a>]. The primary transcript is approximately 5.1 kb in length, encoding a 1,663-amino-acid preproprotein. The gene structure is highly conserved across mammals, with the exon-intron boundaries showing remarkable evolutionary conservation, particularly in regions encoding the thioester-containing domain (TED) and the macroglobulin domains [<a href="#ref-2">2</a>].

The genomic organization of C3 is characterized by several notable features:

- **Promoter Region**: The 5' flanking region contains a TATA-less promoter with multiple transcription start sites. The core promoter spans approximately 300 bp upstream of the translation start site and contains binding sites for several transcription factors including C/EBP (CCAAT/enhancer-binding protein), NF-κB, AP-1, and STAT3 [<a href="#ref-3">3</a>][<a href="#ref-1">1</a>]. A 58-base-pair region located between -352 and -294 relative to the transcription start site has been identified as critical for synergistic induction by interleukin-1 (IL-1) and interleukin-6 (IL-6) [<a href="#ref-3">3</a>].

- **Enhancer Elements**: Multiple enhancer-like elements have been identified in the 5' flanking region and within intronic sequences. The promoter contains a canonical CCAAT box motif at position -70 to -66 that binds nuclear proteins in a tissue-specific manner [<a href="#ref-4">4</a>]. Additionally, a glucocorticoid response element (GRE) half-site and several partial palindromic sequences resembling steroid hormone response elements have been identified in the first intron [<a href="#ref-5">5</a>].

- **CpG Islands**: The promoter region contains a CpG island spanning approximately 1.2 kb, suggesting potential regulation by DNA methylation. Studies have demonstrated that the C3 promoter is hypomethylated in hepatocytes (the primary site of C3 synthesis) but hypermethylated in non-expressing tissues [<a href="#ref-1">1</a>].

### 1.2 Transcriptional Regulation

The transcriptional regulation of C3 is complex and tissue-specific, reflecting its diverse physiological roles. The liver is the primary site of C3 synthesis, contributing approximately 90% of circulating C3. However, extrahepatic expression occurs in macrophages, monocytes, astrocytes, epithelial cells, fibroblasts, and endothelial cells, where local C3 production serves tissue-specific functions [<a href="#ref-6">6</a>][<a href="#ref-1">1</a>].

**Cytokine Regulation**: C3 is a canonical acute-phase protein whose expression is upregulated by pro-inflammatory cytokines. IL-1β and IL-6 synergistically induce C3 transcription through the 58-bp response element in the promoter [<a href="#ref-3">3</a>]. This synergy involves the cooperative binding of C/EBP family members and NF-κB to adjacent sites. IL-1β signaling through the IL-1 receptor activates a cascade involving MKK6, p38 MAPK, and C/EBP-β, which then binds to the C3 promoter [<a href="#ref-2">2</a>]. TNF-α also induces C3 expression through NF-κB activation, although the kinetics differ from IL-1β stimulation [<a href="#ref-3">3</a>][<a href="#ref-4">4</a>].

**Nuclear Receptor Regulation**: Several nuclear receptors modulate C3 expression. Peroxisome proliferator-activated receptor α (PPARα) positively regulates C3 expression in hepatic cells but inhibits TNF-α-mediated activation, suggesting a complex interplay between metabolic and inflammatory signaling [<a href="#ref-3">3</a>]. PPARγ activation by insulin downregulates C3 expression in HepG2 cells, providing a mechanism for metabolic control of complement production [<a href="#ref-5">5</a>]. Glucocorticoids have been shown to enhance C3 expression in pulmonary epithelial cells, potentially contributing to local immune defense in the lung [<a href="#ref-6">6</a>].

**Hypoxic Regulation**: Hypoxia modulates C3 expression in macrophages through HIF-1α-dependent and -independent mechanisms. Under hypoxic conditions, C3 expression is downregulated in human macrophages, potentially affecting local complement activity in ischemic tissues [<a href="#ref-1">1</a>].

**Tissue-Specific Factors**: In the brain, C3 expression in astrocytes is regulated by IL-1β, TNF-α, and IFN-γ, with TGF-β serving as a negative regulator [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>][<a href="#ref-4">4</a>][<a href="#ref-5">5</a>]. The differential regulation by IFN-γ and IL-1β suggests distinct signaling pathways converge on the C3 promoter in glial cells. In the kidney, C3 expression in glomerular epithelial cells and mesangial cells is regulated by IL-1β and TNF-α, contributing to local complement activation in glomerulonephritis [<a href="#ref-6">6</a>][<a href="#ref-6">6</a>][<a href="#ref-4">4</a>].

### 1.3 Alternative Splicing and Isoforms

The C3 gene undergoes limited alternative splicing, with the predominant transcript encoding the full-length preproprotein. However, several minor splice variants have been described:

- **Full-length C3 (canonical)**: Encodes the 1,663-amino-acid preproprotein that undergoes proteolytic processing to generate the mature C3 protein.
- **C3-S (short) variant**: A splice variant lacking exon 13 has been reported in some tissues, potentially generating a truncated protein with altered function, though its physiological significance remains unclear.
- **Intronic retention variants**: RNA-seq data from GTEx and other databases indicate low-level intron retention in specific tissues, which may contribute to nonsense-mediated decay and represent a regulatory mechanism.

The functional significance of C3 splice variants in human disease remains an active area of investigation. Unlike some complement genes (e.g., CFH), no clearly pathogenic splice variants of C3 have been definitively characterized.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Structure

The mature C3 protein (1,641 amino acids after signal peptide cleavage) is a large glycoprotein of approximately 185 kDa. The protein folds into 13 distinct domains arranged in a linear fashion from the N-terminus to the C-terminus. The overall architecture resembles a "V" shape or crescent, with the thioester-containing domain (TED) positioned at the apex [<a href="#ref-1">1</a>].

The domain organization of C3 from N-terminus to C-terminus is as follows:

1. **Macroglobulin domain 1 (MG1)**: Residues 1–130
2. **Macroglobulin domain 2 (MG2)**: Residues 131–250
3. **Macroglobulin domain 3 (MG3)**: Residues 251–370
4. **Macroglobulin domain 4 (MG4)**: Residues 371–490
5. **Macroglobulin domain 5 (MG5)**: Residues 491–610
6. **Macroglobulin domain 6 (MG6)**: Residues 611–730
7. **Macroglobulin domain 7 (MG7)**: Residues 731–850
8. **Linker domain**: Residues 851–900
9. **ANA domain (anaphylatoxin)**: Residues 901–930 (C3a)
10. **Macroglobulin domain 8 (MG8)**: Residues 931–1050
11. **CUB domain (Complement C1r/C1s, Uegf, BMP1)**: Residues 1051–1170
12. **Thioester-containing domain (TED)**: Residues 1171–1330
13. **C345C domain**: Residues 1331–1663

### 2.2 Key Structural Features

**Thioester-Containing Domain (TED)**: The TED domain is the functional hallmark of C3 and related proteins (C4, C5, and α2-macroglobulin). The thioester bond forms between the side chains of cysteine 988 and glutamine 991 (mature protein numbering), creating a reactive intramolecular bond. This bond is essential for covalent attachment of C3 to target surfaces. Upon activation, the thioester is exposed and can react with hydroxyl or amino groups on target surfaces, enabling opsonization [<a href="#ref-1">1</a>]. The TED domain is highly mobile, and its conformational rearrangement is critical for the activation process.

**Anaphylatoxin Domain (C3a)**: The C3a domain (residues 672–748 in the mature protein) is released upon cleavage by C3 convertase. C3a is a 77-amino-acid peptide that functions as a potent anaphylatoxin, mediating inflammation through the C3a receptor (C3aR). The structure of C3a consists of a compact core stabilized by three disulfide bonds, with a C-terminal arginine residue essential for receptor binding.

**C3 Convertase Cleavage Sites**: The protein contains two major cleavage sites for C3 convertases:
- **C3a/C3b cleavage site**: Arg726-Ser727 (cleavage by C3 convertase)
- **C3b/iC3b cleavage site**: Arg954-Ser955 (cleavage by Factor I with cofactors)

**Factor H and CR1 Binding Sites**: Multiple binding sites for regulatory proteins have been mapped to specific domains. Factor H binds to the MG domains and the TED domain, while complement receptor 1 (CR1) interacts with the CUB domain and MG domains.

### 2.3 Post-Translational Modifications

C3 undergoes extensive post-translational processing:

1. **Signal peptide cleavage**: Removal of the 22-amino-acid signal peptide in the endoplasmic reticulum.
2. **Proteolytic processing**: Cleavage of the Arg659-Arg660 bond by furin or related proprotein convertases to generate the mature two-chain protein (β-chain: 645 amino acids; α-chain: 992 amino acids) linked by disulfide bonds.
3. **N-glycosylation**: Four N-linked glycosylation sites (Asn-917, Asn-1020, Asn-1482, Asn-1552) are occupied with complex-type oligosaccharides.
4. **Thioester formation**: Autocatalytic formation of the internal thioester bond during protein folding.

### 2.4 Conformational States

C3 exists in multiple conformational states that are critical for its function:

- **Native C3**: The inactive pro-form with the thioester buried within the TED domain.
- **C3(H2O)**: A conformationally altered form generated by spontaneous hydrolysis of the thioester, which mimics C3b and can initiate the alternative pathway.
- **C3b**: The activated form generated by proteolytic cleavage, which exposes the thioester and multiple binding sites for downstream components.
- **iC3b**: The inactivated form generated by Factor I cleavage of C3b, which retains opsonin function but cannot participate in the convertase.
- **C3c and C3dg**: Further degradation products with distinct functions.

The conformational transitions between these states involve large-scale domain rearrangements, particularly movement of the TED domain from a buried to an exposed position [<a href="#ref-1">1</a>].

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load C3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01024)

The interactive visualizer allows exploration of the C3 structure in three dimensions, including domain organization, key catalytic residues, and binding interfaces. Users can toggle between different conformational states (native C3, C3b, C3c) and highlight specific domains or mutations.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Complement Cascade

C3 occupies the central position in the complement cascade, serving as the convergence point for all three activation pathways. The classical pathway is initiated by antibody-antigen complexes, the lectin pathway by carbohydrate patterns on pathogen surfaces, and the alternative pathway by spontaneous C3 hydrolysis or foreign surface recognition.

**Classical and Lectin Pathways**: Both pathways converge on the formation of the C3 convertase (C4b2a), which cleaves C3 into C3a and C3b. The C3b generated can then participate in the formation of the C5 convertase (C4b2a3b), leading to MAC formation.

**Alternative Pathway**: The alternative pathway is unique in that it continuously operates at a low level through spontaneous C3 hydrolysis. C3(H2O) binds Factor B, which is cleaved by Factor D to form the initial C3 convertase (C3(H2O)Bb). This convertase generates C3b, which can bind to surfaces and form additional convertases (C3bBb), creating an amplification loop. Properdin stabilizes the alternative pathway convertase, while Factor H and Factor I regulate its activity.

### 3.2 C3 Activation and Effector Functions

The cleavage of C3 by C3 convertases generates two key fragments with distinct functions:

**C3a (Anaphylatoxin)**: C3a is a 9-kDa peptide that signals through the G-protein-coupled receptor C3aR. C3a mediates:
- Mast cell degranulation and histamine release
- Smooth muscle contraction
- Chemotaxis of eosinophils and mast cells
- Regulation of Th2 immune responses
- Modulation of dendritic cell function

**C3b (Opsonin)**: C3b covalently attaches to target surfaces through its reactive thioester. Surface-bound C3b mediates:
- Opsonization for phagocytosis via complement receptors (CR1, CR3, CR4)
- Formation of C5 convertase for MAC assembly
- Immune complex clearance through erythrocyte CR1
- Enhancement of B cell responses through CR2 (CD21)

### 3.3 Intracellular Complement System

Recent evidence has revealed an intracellular complement system (complosome) with functions distinct from the extracellular cascade [<a href="#ref-2">2</a>]. C3 and its activation fragments are present within cells, where they participate in:

- **T cell metabolism**: Intracellular C3 activation generates C3a and C3b, which regulate mTOR signaling and autophagy in T cells.
- **Cell survival**: C3 activation within cells protects against apoptosis through regulation of mitochondrial function.
- **Gene transcription**: Internalized C3 can interact with DNA and modulate gene expression in B cells [<a href="#ref-2">2</a>].

The intracellular complement system represents a novel paradigm in complement biology, linking immune function to cellular metabolism and survival.

### 3.4 C3 in Neurobiology

C3 plays a critical role in the central nervous system, where it mediates synaptic pruning during development and in disease [<a href="#ref-3">3</a>][<a href="#ref-4">4</a>][<a href="#ref-5">5</a>]. Astrocyte-derived C3 tags synapses for elimination by microglia through CR3 (CD11b/CD18). This process is essential for normal brain development but contributes to neurodegeneration when dysregulated.

In glaucoma, C3 upregulation in the retina and optic nerve precedes neuronal damage, and C3-targeted gene therapy can restrict neurodegeneration [<a href="#ref-3">3</a>]. In schizophrenia, increased C3 expression in the midbrain is associated with the "high inflammatory/immune biotype" observed in approximately half of cases [<a href="#ref-4">4</a>]. The complement system's role in synaptic pruning has been implicated in the synaptic loss characteristic of schizophrenia.

### 3.5 C3 in Metabolism and Cardiovascular Disease

C3 functions as an adipokine and is associated with metabolic syndrome and cardiovascular disease [<a href="#ref-6">6</a>]. C3 expression in adipose tissue is regulated by insulin and PPARγ [<a href="#ref-5">5</a>], and circulating C3 levels correlate with body mass index, insulin resistance, and cardiovascular risk. The mechanisms linking C3 to metabolic disease include:

- **Acylation-stimulating protein (ASP)**: C3a desArg (ASP) is generated by carboxypeptidase cleavage of C3a and stimulates triglyceride synthesis in adipocytes.
- **Inflammation**: C3-mediated inflammation contributes to adipose tissue dysfunction and insulin resistance.
- **Lipid metabolism**: C3 interacts with lipoproteins and may influence lipid clearance.

### 3.6 Protein-Protein Interaction Network

C3 participates in an extensive protein-protein interaction network involving:

**Activators and Convertases**:
- Factor B (CFB)
- Factor D (CFD)
- C4b2a (classical pathway C3 convertase)
- C3bBb (alternative pathway C3 convertase)

**Regulators**:
- Factor H (CFH)
- Factor I (CFI)
- Complement receptor 1 (CR1/CD35)
- Membrane cofactor protein (MCP/CD46)
- Decay-accelerating factor (DAF/CD55)
- C4b-binding protein (C4BP)
- Properdin (CFP)

**Receptors**:
- C3a receptor (C3aR)
- Complement receptor 2 (CR2/CD21)
- Complement receptor 3 (CR3/ITGAM-ITGB2)
- Complement receptor 4 (CR4/ITGAX-ITGB2)
- Complement receptor of the immunoglobulin superfamily (CRIg)

**Downstream Effectors**:
- C5 (cleaved by C5 convertase)
- C6, C7, C8, C9 (MAC components)

```mermaid
sequenceDiagram
    participant AP as "Alternative Pathway"
    participant CP as "Classical Pathway"
    participant LP as "Lectin Pathway"
    participant C3 as "C3"
    participant C3a as "C3a"
    participant C3b as "C3b"
    participant C5 as "C5"
    participant MAC as "Membrane Attack Complex"
    AP->>C3: Spontaneous hydrolysis (C3(H2O))
    CP->>C3: C4b2a convertase
    LP->>C3: C4b2a convertase
    
    C3->>C3a: Cleavage by convertases
    C3->>C3b: Cleavage by convertases
    
    C3a->>C3aR: Anaphylatoxin signaling
    C3b->>C5: C5 convertase formation
    C3b->>Opsonization: CR1/CR3/CR4 binding
    
    C5->>MAC: C5b-9 assembly
    MAC->>Cell Lysis: Pore formation
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Complement-Mediated Kidney Diseases

C3 mutations are strongly associated with a spectrum of complement-mediated kidney diseases, including C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), and dense deposit disease (DDD) [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>][<a href="#ref-3">3</a>][<a href="#ref-4">4</a>][<a href="#ref-5">5</a>][<a href="#ref-6">6</a>].

**C3 Glomerulopathy (C3G)**: C3G is characterized by predominant C3 deposition in the glomerulus with minimal immunoglobulin deposition. It encompasses C3 glomerulonephritis (C3GN) and DDD, which share similar disease courses [<a href="#ref-1">1</a>]. Genetic variants in C3 are found in approximately 20-25% of C3G patients [<a href="#ref-2">2</a>][<a href="#ref-6">6</a>]. The pathogenic mechanisms include:

- **Gain-of-function mutations**: Variants that increase C3 convertase resistance to regulation or enhance convertase formation.
- **Loss-of-function mutations in regulators**: Mutations in CFH, CFI, CFHR5, and other regulators that reduce complement control [<a href="#ref-3">3</a>][<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].
- **Hybrid genes**: Fusion genes involving CFHR3-CFHR1 or CFHR5-CFHR2 that generate dysregulated complement proteins [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>].

**Atypical Hemolytic Uremic Syndrome (aHUS)**: aHUS is a thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury. C3 mutations account for approximately 5-10% of aHUS cases [<a href="#ref-1">1</a>][<a href="#ref-5">5</a>]. The pathogenic variants typically result in:

- **Resistance to Factor H-mediated regulation**: Mutations in the Factor H binding sites on C3.
- **Enhanced C3 convertase stability**: Mutations that increase the half-life of C3bBb.
- **Impaired Factor I cofactor activity**: Mutations that reduce C3b inactivation.

A notable case report described a patient with aHUS and a C3 gene mutation who experienced numerous relapses but had a favorable 20-year outcome with appropriate management [<a href="#ref-1">1</a>]. Another case demonstrated successful treatment of recurrent post-transplant HUS associated with C3 mutation using eculizumab [<a href="#ref-4">4</a>].

### 4.2 Age-Related Macular Degeneration (AMD)

AMD is a leading cause of blindness in the elderly, and complement dysregulation is a central pathogenic mechanism. The C3 gene contains several common polymorphisms associated with AMD susceptibility:

- **R102G (rs2230199)**: This polymorphism in the C3 gene is associated with increased risk of AMD, particularly exudative AMD [<a href="#ref-5">5</a>][<a href="#ref-6">6</a>]. The glycine variant (G) is the risk allele, with an odds ratio of approximately 1.5-2.0 for homozygous carriers.
- **K155Q (rs147859257)**: A rare variant associated with reduced C3 function and protection against AMD [<a href="#ref-1">1</a>].
- **Other variants**: Multiple rare variants in C3 have been identified in AMD patients, though their individual contributions are modest [<a href="#ref-1">1</a>].

The association of C3 variants with AMD is consistent across different populations, including French [<a href="#ref-5">5</a>], Chinese [<a href="#ref-2">2</a>], and Czech [<a href="#ref-6">6</a>] cohorts.

### 4.3 Systemic Lupus Erythematosus (SLE)

C3 polymorphisms have been associated with susceptibility to SLE [<a href="#ref-3">3</a>]. The complement system plays a dual role in SLE: complement deficiency predisposes to autoimmunity through impaired immune complex clearance, while complement activation contributes to tissue damage. C3 variants may influence both processes.

A case report described a patient with lupus nephritis, autoantibodies to complement alternative pathway proteins, and a C3 gene mutation [<a href="#ref-4">4</a>]. This case illustrates the complex interplay between genetic variants and autoimmune responses in complement-mediated disease.

### 4.4 Pregnancy Complications

**Preeclampsia**: C3 gene variants have been associated with susceptibility to severe preeclampsia [<a href="#ref-1">1</a>]. The complement system is activated in the placenta during normal pregnancy, and dysregulation may contribute to the endothelial dysfunction characteristic of preeclampsia.

**Recurrent Pregnancy Loss**: Analysis of C3 gene variants in patients with idiopathic recurrent spontaneous pregnancy loss identified potentially pathogenic variants in a subset of patients [<a href="#ref-5">5</a>]. The complement system is essential for normal pregnancy, and dysregulation may contribute to miscarriage.

### 4.5 Infections

**C3 Deficiency**: Complete C3 deficiency is a rare autosomal recessive disorder characterized by severe, recurrent bacterial infections, particularly with encapsulated organisms such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae [<a href="#ref-6">6</a>][<a href="#ref-1">1</a>]. The first confirmed case of C3 deficiency caused by compound heterozygous mutations was reported in 2008 [<a href="#ref-6">6</a>]. Homozygous hereditary C3 deficiency can result from partial gene deletion [<a href="#ref-1">1</a>].

**Recurrent Pneumococcal Infection**: A novel C3 gene mutation was identified in a patient with recurrent invasive pneumococcal infection, providing insight into vaccine development for complement-deficient patients [<a href="#ref-2">2</a>].

### 4.6 Rheumatoid Arthritis (RA)

C3 gene functional polymorphisms and serum C3 levels have been studied in RA patients [<a href="#ref-3">3</a>]. C3 is a central molecule in the inflammatory process of RA, and variations in the C3 gene may influence disease susceptibility and severity. The study by Sena et al. examined C3 polymorphisms and serum levels in RA patients, finding associations with disease activity [<a href="#ref-3">3</a>].

### 4.7 Other Disease Associations

- **Asthma**: C3 variants are associated with asthma and related phenotypes, particularly in African Caribbean populations [<a href="#ref-4">4</a>][<a href="#ref-5">5</a>].
- **Atopic Dermatitis**: Polymorphisms within the C3 gene are associated with specific IgE levels to common allergens in atopic dermatitis patients [<a href="#ref-6">6</a>].
- **Uveitis**: A study found no association of C3 gene variants with uveitis, suggesting that C3 may not be a major susceptibility gene for this condition [<a href="#ref-1">1</a>].
- **Temporal Lobe Epilepsy**: A functional variant in the C3 gene promoter was associated with genetic susceptibility to temporal lobe epilepsy and febrile seizures [<a href="#ref-2">2</a>].
- **Diabetic Nephropathy**: C3 has been identified as a potential therapeutic target for diabetic nephropathy through bioinformatics analysis [<a href="#ref-3">3</a>][<a href="#ref-4">4</a>].
- **Schizophrenia**: Increased C3 expression in the midbrain is associated with schizophrenia [<a href="#ref-4">4</a>].

### 4.8 Pathogenic Variant Classification

The ClinVar database contains numerous C3 variants with varying classifications. Key pathogenic variants include:

| **Variant** | **Protein Change** | **Disease Association** | **Mechanism** |
|---|---|---|---|
| c.481C>T | R161W | C3G, aHUS | Impaired Factor H binding |
| c.2038G>A | E680K | aHUS | Enhanced convertase stability |
| c.2179C>T | R727W | C3G | Impaired regulation |
| c.3040C>T | R1014C | C3G | Disrupted thioester function |
| c.3328G>A | D1110N | C3G | Impaired Factor I cofactor activity |
| c.3648C>T | T1216M | C3G | Reduced C3b degradation |

## 5. Host-Pathogen & Viral Interactions

### 5.1 Microbial Evasion of C3

Pathogens have evolved diverse strategies to evade or exploit C3-mediated immunity:

**Staphylococcus aureus**: S. aureus produces multiple complement evasion proteins, including:
- **Staphylococcal complement inhibitor (SCIN)**: Blocks C3 convertase activity.
- **Extracellular fibrinogen-binding protein (Efb)**: Binds C3 and inhibits opsonization.
- **Staphylococcal superantigen-like protein 7 (SSL7)**: Binds C5 and inhibits MAC formation.

**Streptococcus pyogenes**: Produces M protein, which binds Factor H and C4BP to inhibit complement activation.

**Neisseria species**: Express sialylated lipooligosaccharide that enhances Factor H binding, promoting complement evasion.

**Pseudomonas aeruginosa**: Produces elastase that cleaves C3 and inactivates complement.

**Viruses**: Several viruses have developed mechanisms to evade complement:
- **Herpes simplex virus (HSV)**: Expresses glycoprotein C that binds C3 and inhibits complement activation.
- **Vaccinia virus**: Produces complement control proteins that mimic host regulators.
- **HIV**: Incorporates host complement regulators into its envelope to resist complement-mediated lysis.

### 5.2 C3 as a Pathogen Receptor

Some pathogens exploit C3 for cellular entry:

- **Epstein-Barr virus (EBV)**: Uses CR2 (CD21), which binds C3d fragments, for B cell entry.
- **Measles virus**: Uses CD46 (MCP), a C3b/C4b-binding protein, as a receptor.
- **Adenovirus**: Uses CD46 for entry into certain cell types.

### 5.3 C3 in Bacterial Toxins

The bacterial C3 exoenzyme (from Clostridium botulinum) is an ADP-ribosyltransferase that modifies Rho GTPases, not complement C3 [<a href="#ref-5">5</a>][<a href="#ref-6">6</a>][<a href="#ref-1">1</a>]. This nomenclature confusion has led to some misunderstanding in the literature. The botulinum C3 exoenzyme is used experimentally to inhibit RhoA signaling and has been explored for therapeutic applications in glaucoma [<a href="#ref-2">2</a>][<a href="#ref-3">3</a>][<a href="#ref-4">4</a>].

### 5.4 C3 in Invertebrate Immunity

C3-like genes have been characterized in various invertebrate species, including razor clams (Sinonovacula constricta) [<a href="#ref-5">5</a>][<a href="#ref-6">6</a>] and shrimp (Litopenaeus vannamei) [<a href="#ref-1">1</a>]. These studies reveal the evolutionary conservation of C3-mediated immunity and its role in innate immune responses, including hemolysis and bacteriolytic activities.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Therapies

**Eculizumab (Soliris)**: A humanized monoclonal antibody against C5 that blocks MAC formation. While not directly targeting C3, eculizumab is effective in treating complement-mediated diseases with C3 involvement, including:
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)
- C3 glomerulopathy (off-label use)
- Myasthenia gravis (anti-AChR antibody-positive)

Eculizumab has been shown to induce long-term remission in recurrent post-transplant HUS associated with C3 gene mutation [<a href="#ref-4">4</a>].

**Pegcetacoplan (Empaveli)**: A C3-targeted pegylated peptide that inhibits C3 cleavage. Approved for PNH, it represents the first FDA-approved therapy directly targeting C3.

### 6.2 Investigational Therapies

**C3-Targeted Therapies**:
- **AMY-101**: A compstatin-based C3 inhibitor in clinical trials for C3G and other complement-mediated diseases.
- **Cp40**: A compstatin analog with improved potency and pharmacokinetic properties.
- **ALXN2040 (danicopan)**: A Factor D inhibitor that blocks the alternative pathway, reducing C3 activation.

**Gene Therapy Approaches**:
- **C3-targeted gene therapy for glaucoma**: A study demonstrated that complement C3-targeted gene therapy restricts onset and progression of neurodegeneration in chronic mouse glaucoma [<a href="#ref-3">3</a>].
- **CRISPR/Cas9-mediated C3 knockout**: Generation of C3-deficient pigs using CRISPR/Cas9 has been achieved, providing large animal models for studying C3 function [<a href="#ref-2">2</a>].

### 6.3 Pharmacogenomic Considerations

C3 genetic variants can influence response to complement-targeted therapies:

- **Eculizumab response**: Patients with C3 mutations that cause uncontrolled C3 activation may have variable responses to C5 inhibition, as C3 fragments continue to drive inflammation.
- **Compstatin-based therapies**: The efficacy of C3 inhibitors may be influenced by C3 levels and specific mutations affecting drug binding.
- **Lipid-modifying therapies**: C3 gene variants in the APOA1/C3/A4/A5 cluster influence lipid responses to fenofibrate [<a href="#ref-3">3</a>].

### 6.4 C3 as a Biomarker

C3 levels and genetic variants serve as biomarkers in various diseases:

- **C3 glomerulopathy**: Low C3 levels are characteristic and correlate with disease activity.
- **AMD**: C3 variants are used in genetic risk prediction models.
- **Cardiometabolic disease**: C3 levels are associated with cardiovascular risk [<a href="#ref-6">6</a>].
- **Diabetic nephropathy**: C3 has been identified as an immune infiltration-related biomarker [<a href="#ref-3">3</a>].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 718 | https://www.ncbi.nlm.nih.gov/gene/718 |
| Ensembl | ENSG00000125730 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125730 |
| UniProt | P01024 | https://www.uniprot.org/uniprotkb/P01024 |
| RCSB PDB | 2A73 (native C3) | https://www.rcsb.org/structure/2A73 |
| RCSB PDB | 3CZT (C3b) | https://www.rcsb.org/structure/3CZT |
| RCSB PDB | 2XQW (C3c) | https://www.rcsb.org/structure/2XQW |
| ClinVar | C3 | https://www.ncbi.nlm.nih.gov/clinvar/?term=C3%5Bgene%5D |
| OMIM | 120700 | https://www.omim.org/entry/120700 |
| GeneCards | GC19P006677 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=C3 |
| GTEx | C3 | https://gtexportal.org/home/gene/C3 |
| STRING | P01024 | https://string-db.org/network/P01024 |
| BioGRID | 107590 | https://thebiogrid.org/107590 |
| Reactome | R-HSA-166786 | https://reactome.org/content/detail/R-HSA-166786 |
| KEGG | hsa:718 | https://www.genome.jp/dbget-bin/www_bget?hsa:718 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Endopeptidase inhibitor activity | GO:0004866 |
| Molecular Function | Complement component C3b binding | GO:0001850 |
| Molecular Function | Opsonin binding | GO:0001849 |
| Biological Process | Complement activation, alternative pathway | GO:0006957 |
| Biological Process | Complement activation, classical pathway | GO:0006958 |
| Biological Process | Innate immune response | GO:0045087 |
| Biological Process | Inflammatory response | GO:0006954 |
| Biological Process | Synaptic pruning | GO:0098883 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Blood microparticle | GO:0072562 |
| Cellular Component | Cell surface | GO:0009986 |

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Bogomolova, A., Shavva, V., Nikitin, A. A., Nekrasova, E. V., Dizhe, E., Larionova, E., Kudriavtsev, I., & Orlov, S. V. (2019). Hypoxia as a Factor Involved in the Regulation of the apoA-1, ABCA1, and Complement C3 Gene Expression in Human Macrophages. Biochemistry (Moscow). https://www.semanticscholar.org/paper/2704a8b20f9862bdbb0bca79f5f4ddf2080b9191

<a id="ref-2"></a>[2] Lokki, A., Kaartokallio, T., Holmberg, V., Onkamo, P., Koskinen, L., Saavalainen, P., Heinonen, S., Kajantie, E., Kere, J., Kivinen, K., Pouta, A., Villa, P., Hiltunen, L., Laivuori, H., & Meri, S. (2017). Analysis of Complement C3 Gene Reveals Susceptibility to Severe Preeclampsia. Frontiers in Immunology. https://www.semanticscholar.org/paper/b5d2845623274a95e2749e632655b3adb867d5a8

<a id="ref-3"></a>[3] Sena, L., Oliveira-Toré, C. F., Skare, T., de Messias-Reason, I. D., & Andrade, F. (2020). C3 Gene Functional Polymorphisms and C3 Serum Levels in Patients with Rheumatoid Arthritis. Immunological Investigations. https://www.semanticscholar.org/paper/fa45e580c243d14b5c1fb7631a01064cc9e572f4

<a id="ref-4"></a>[4] Mohlin, F., Gros, P., Mercier, É., Gris, J., & Blom, A. (2018). Analysis of C3 Gene Variants in Patients With Idiopathic Recurrent Spontaneous Pregnancy Loss. Frontiers in Immunology. https://www.semanticscholar.org/paper/2cc217e51b1fae8c1168c6c2a85083012fa152fc

<a id="ref-5"></a>[5] Yang, M., Wang, J., Dong, L., Kong, D., Teng, Y., Liu, P., Fan, J., Yu, X. (2017). Lack of association of C3 gene with uveitis: additional insights into the genetic profile of uveitis regarding complement pathway genes. Scientific Reports. https://www.semanticscholar.org/paper/0b7d2bece821e8704e1b4e469d9b7b921e092200

<a id="ref-6"></a>[6] Peng, M., Niu, D., Chen, Z., Lan, T., Dong, Z